Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(OTCQB:OXYS) Huge Upside 100 % Gain Possible - (OTCBB:RGBP) Opportunity Knocks !!

Oxygen from Powder

www.oxysure.com (OTCPK:OXYS)

http://finance.yahoo.com/q?s=OXYS

To View These Headlines and More Visit the Yahoo Link Above

OxySure Systems Named as Supplier of Backup Support, Medical Equipment for Health Services at Special Olympics World Games Los Angeles 2015 (LA2015)Marketwired(Wed, June 24)

(Global Exposure-New Contract-Potential-An Honor)

** Could result in $32 Million in Revenue over 5 Years !!

OxySure and Z-Medica Sign Distribution AgreementMarketwired(Mon, Jun 15)

(Emergency Medical Market Exposure-New Product)

** New Distribution Partner !!

OxySure Unveils Plans to Add Drones for Emergency UseMarketwired(Tue, Jun 2)

(Military-EMS-Search & Rescue-Humanitarian Aid)

(Zero Manufacturing Costs-Cost Built Into Package)

(Purchasers Assume-Cover Manufacturing Costs)

** $3,000 - $7,000 Approx per Make/Model and Payload REVENUE Potential is Huge !!

OxySure Territorial Sales Managers 25-30 By Year End 2015

(Appointments/Training Could Leak Into Q1 2016)

(Minimum Quota Per TSM $500,000 Per Year)

** Minimum 25 TSM's/Minimum Quota Met $500K each = $12.5 Million New Revenue 2016 !!

We Believe OXYS is a LONG PLAY with Short Term Gain Potential

Advantageous Entry or Cost Average Level

OXYS "Saving Lives Daily"

** Should you want or need more information please contact us :

Regen BioPharma, Inc. (OTCBB:RGBP)

http://regenbiopharma.com/

http://finance.yahoo.com/q?s=RGBP

** To View These Headlines and More Visit the Yahoo Link Above

Regen BioPharma Dually Trades on the (OTCBB) & (OTCPINK)

What makes Regen BioPharma and attractive situation ? And why you should seriously take a closer look:

RGBP was selected and accepted for presentation at the (what is considered to be the "Premier" Conference/Society for Stem Cell research) International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden.

RGBP "Patented" New Drugs and the recent announcement of a "Filing" for a New "Patent" on a Drug geared towards treating "Leukemia.

RGBP brought on an "Expert" in the field of Cancer Research, who possibly could be instrumental in answering the "Final/Last Phase" of clinical trials and queries from the FDA prior to clearance/approval of dCellVax (treatment for Breast Cancer).

RGBP has "Engaged" Charles River Laboratories to initiate a Good Laboratory Practices <GLP> mouse toxicity study with regards to "HemaXellerate". HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow. That could be the "Last Step" prior to FDA clearance/approval for HemaXellerate.

RGBP a "Prime Candidate" to be bought out by a "Larger Pharma" ? (Chief Scientific Director Thomas Ichim PhD was CEO of Medi Stem when it was bought out for $26 Million)

** We think all of the above apply to the situation !! And that this virtually "Unknown Sleeper" will one day be the "Leader" in the Breast/Cancer-Rare Blood Disorder /Disease Stem Cell Sector. You know the old saying get in low, sell high.

**We believe Regen BioPharma is a LONG PLAY, with SHORT Term GAIN Potential.

> If you have any questions, please feel free to contact us.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.